OncoMatch/Clinical Trials/NCT07362914
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
Is NCT07362914 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Dexamethasone (12mg d1) and Dexamethasone (2mg QD, d1-5,) for breast cancer.
Treatment: Dexamethasone (12mg d1) · Dexamethasone (2mg QD, d1-5,) · Doxorubicin hydrochloride liposome · Cyclophosphamide — Investigating the Association Between Corticosteroid Use and Improvement in Doxorubicin Liposome-Induced Cutaneous Toxicity: Exploring the Feasibility and Mechanisms of Corticosteroids in Mitigating Liposomal Doxorubicin-Related Dermatologic Adverse Effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: radiotherapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: biologics
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: targeted therapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: immunotherapy
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: antitumor treatments
Exception: washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy)
Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter).
Cannot have received: liposomal doxorubicin or similar formulations
Previous treatment with liposomal doxorubicin or similar formulations.
Lab requirements
Blood counts
ANC ≥1.5 × 10⁹/L, Platelet count ≥75 × 10⁹/L, Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min
Liver function
Non-liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤2.5 × ULN; Liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤5 × ULN
Cardiac function
LVEF >50%, no severe arrhythmias/conduction abnormalities, no history of myocardial infarction, CABG, or heart failure (NYHA Class ≥II), QTcF ≤450 ms (males), ≤470 ms (females)
Hematologic: ANC ≥1.5 × 10⁹/L, Platelet count ≥75 × 10⁹/L, Hemoglobin ≥90 g/L; Hepatic: Non-liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤2.5 × ULN; Liver metastasis: TBIL ≤1.5 × ULN, ALT and AST ≤5 × ULN; Renal: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min; Coagulation: INR or PT ≤1.5 × ULN, APTT ≤1.5 × ULN; Cardiac: LVEF >50%, no severe arrhythmias/conduction abnormalities, no history of myocardial infarction, CABG, or heart failure (NYHA Class ≥II), QTcF ≤450 ms (males), ≤470 ms (females)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07362914 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, biologics disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages